

11 November 2024

ASX Announcement

Board changes

MELBOURNE Australia, 11 November 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) advises that Dr Paul MacLeman and Dr Anna Lavelle have advised of their intentions to retire from the Island Board following the Company's 2024 Annual General Meeting.

Island's Managing Director and CEO, Dr David Foster said, *"I extend my sincere thanks to Paul MacLeman, for his many significant contributions and his leadership as Executive Chair at Island. Paul was instrumental in our ASX IPO and his dedication and his vision has been paramount in driving forward the company's strategy, pipeline evolution and clinical program. Moreover, I am personally grateful for the guidance Paul has provided over the last four years.*

"My thanks also goes to Anna Lavelle. The stewardship and guidance provided across her many areas of expertise has helped us progress our strategic agenda and seen us deliver many clinical milestones. I am grateful for Anna's deep connections in the industry and the extreme professionalism she exhibited throughout her time with Island. I wish Paul and Anna all the very best in their next chapters."

Given the board changes, Resolutions 3, 11 and 13 at the 2024 Annual General Meeting Notice of Meeting which is being held on Tuesday, 19 November 2024 at 9:00am (AEDT) relating to Dr Paul MacLeman and Dr Anna Lavelle will be withdrawn. Any votes submitted on Resolution 3, 11 and 13 will be disregarded and shareholders are not required to do anything further.

The Company will announce a new Chair of the board in due course.

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

Dr Paul MacLeman (Executive Chairman) and David Foster (CEO and Managing Director), Island Pharmaceuticals Limited



Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.